July 14, 2020
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3720
Mary Beth Breslin
ALX Oncology Holdings Inc.
Registration Statement on Form S-1
(File No. 333-239490)
Requested Date: Thursday, July 16, 2020
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, ALX Oncology Holdings Inc. (the Company) hereby requests that the above-referenced Registration Statement on Form S-l (File No. 333-239490) (the Registration Statement) be declared effective at the Requested Date and Requested Time set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Michael Coke at (650) 565-3596.
[Signature page follows]
ALX ONCOLOGY HOLDINGS INC.
|/s/ Jaume Pons|
Jaume Pons, Ph.D.
President and Chief Executive Officer
|cc (w/o enclosures):|| |
Peter García, ALX Oncology Holdings Inc.
Jason Trimborn, KPMG LLP
Brittany Bockman, KPMG LLP
Dave Peinsipp, Cooley LLP
Kristin VanderPas, Cooley LLP
Michael Coke, Wilson Sonsini Goodrich & Rosati, P.C.
Christina Poulsen, Wilson Sonsini Goodrich & Rosati, P.C.